Prophylactic use of myelopoietic growth factors in children after myelosuppressive chemotherapy: Does it pay?

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 6, 2003, Pages 435-440

  Bessmertny, Olga ^a   Cairo, Mitchell S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; VINCRISTINE;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEBRILE NEUTROPENIA; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS; CHILD; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA; NEUTROPENIA;

EID: 0037940021     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200306000-00003     Document Type: Review

References (26)

1. Abu-Ghosh A, Bracho F, Kirov I, et al. Hematopoietic colony-stimulating factors. In Grenvik A, Ayers SM, Holbrook PR, et al. eds. Textbook of Critical Care. Philadelphia: WB Saunders, 2000:542-561
2. Cairo MS, Suen Y, Sender L, et al. Circulating granulocyte colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation: Endogenous G-CSF production correlates with myeloid engraftment. Blood. 1992;79:1869-1873.
3. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol. 1996;14:1957-1960.
4. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18:3558-3585.
5. Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol. 2002;116:28-56.
6. Cairo MS. Myelopoietic growth factors after stem cell transplantation: does it pay? J Pediatr Hematol Oncol. 2001;23:2-6.
7. Welte K, Reiter A, Mempel K, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood. 1996;87:3143-3150.
8. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med. 1997;336:1781-1787.
9. Laver J, Amylon M, Desai S, et al. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol. 1998;16:522-526.
10. Bennett CL, Stinson TJ, Lane D, et al. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol. 2000;34:92-96.
11. Clarke V, Dunstan FD, Webb DK. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med Pediatr Oncol. 1999;32:331-335.
12. Michel G, Landman-Parker J, Auclerc MF, et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18:1517-1524.
13. Delorme J, Badin S, Le Corroller AG, et al. Economic evaluation of recombinant colony-stimulating factor in very high risk childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003;325:441-447.
14. Patte C, Laplanche A, Bertozzi AI, et al. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. J Clin Oncol. 2002;20:441-448.
15. Rubino C, Laplanche A, Patte C, et al. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma. J Natl Cancer Inst. 1998;90:750-755.
16. Little MA, Morland B, Chisholm J, et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol. 2002;38:98-103.
17. Alonzo TA, Kobrinsky NL, Aledo A, et al. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. J Pediatr Hematol Oncol. 2002;24:627-635.
18. Dana WJ. Assessing the relevance of outcomes data for colony-stimulating factors. J Managed Care Pharm. 2000;6:144-150.
19. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99:580-588.
20. Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor following ifosfamide, carboplatin, and etoposide (ICE) in children with recurrent or refractory solid tumors: A Children's Cancer Group report. J Pediatr Hematol Oncol. 2001;23:30-38.
21. Bracho F, Krailo MD, Shen V, et al. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin Cancer Res. 2001;7:58-67.
22. Michon JM, Hartmann O, Bouffet E, et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer. 1998;34:1063-1069.
23. Wexler LH, Weaver-McClure L, Steinberg SM, et al. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol. 1996;14:901-910.
24. Burdach SE, Muschenich M, Josephs W, et al. Granulocyte-macrophage colony-stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study. Cancer. 1995;76:510-516.
25. Housholder SE, Rackoff WR, Goldman J, et al. A case-control retrospective study of the efficacy of granulocyte-colony-stimulating factor in children with neuroblastoma. Am J Pediatr Hematol Oncol. 1994;16:132-137.
26. Marina N, Shema S, Bowman L, et al. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol. 1994;23:328-334.